We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
+15.1%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$59.7M
Cap. Flow
+$48.5M
Cap. Flow %
25.99%
Top 10 Hldgs %
63.01%
Holding
43
New
19
Increased
10
Reduced
9
Closed
5
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
1 year

Sector Composition

Rank Sector Weight
1 Healthcare 97.15%
2 Miscellaneous 2.53%
3 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
PRTA icon
1
Prothena
PRTA
$429M
$19.5M 10.43%
321,093
-228,907
-42% -$7.24M
2020 Q3
8 quarters
HZNP
2
DELISTED
Horizon Therapeutics
HZNP
$18.8M 10.05%
+303,000
New +$21.2M
2022 Q3
0 quarters
LKFT icon
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.25B
$17.3M 9.25%
405,000
+36,000
+10% +$1.84M
2021 Q1
6 quarters
KZR icon
4
DELISTED
Kezar Life Sciences
KZR
$11.4M 6.13%
132,790
+6,521
+5% +$634K
2021 Q1
6 quarters
ALKS icon
5
Alkermes
ALKS
$7.87B
$11.2M 6.01%
+502,150
New +$13.1M
2022 Q3
0 quarters
ALBO
6
DELISTED
Albireo Pharma Inc
ALBO
$9.5M 5.09%
491,244
+23,449
+5% +$485K
2018 Q3
16 quarters
MGTX icon
7
MeiraGTx Holdings
MGTX
$813M
$9.28M 4.97%
1,103,365
+117,147
+12% +$1.03M
2022 Q1
2 quarters
KALV icon
8
DELISTED
KalVista Pharmaceuticals
KALV
$7.69M 4.12%
530,062
-290,690
-35% -$4.06M
2021 Q2
5 quarters
CRL icon
9
Charles River Laboratories
CRL
$16B
$6.54M 3.5%
33,220
+5,720
+21% +$1.23M
2021 Q4
3 quarters
ALDX icon
10
Aldeyra Therapeutics
ALDX
$40.5M
$6.47M 3.46%
1,210,800
-775,083
-39% -$4.65M
2018 Q4
15 quarters
HUM icon
11
Humana
HUM
$46.3B
$6.21M 3.33%
+12,800
New +$6.23M
2022 Q3
0 quarters
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$6.04B
$5.99M 3.21%
285,000
+123,473
+76% +$2.97M
2022 Q1
2 quarters
THC icon
13
Tenet Healthcare
THC
$21.6B
$5.26M 2.82%
102,000
+51,300
+101% +$3.04M
2022 Q2
1 quarter
JNJ icon
14
Johnson & Johnson
JNJ
$656B
$5.18M 2.77%
+31,704
New +$5.36M
2022 Q3
0 quarters
QDEL icon
15
QuidelOrtho
QDEL
$657M
$4.5M 2.41%
62,900
+16,324
+35% +$1.46M
2022 Q1
2 quarters
CUE icon
16
Cue Biopharma
CUE
$34.6M
$3.45M 1.85%
51,519
-3,664
-7% -$315K
2019 Q4
11 quarters
PRTA icon
17
CALL
Prothena
PRTA
$429M
$3.22M 1.72%
+53,100
New +$1.68M
2022 Q3
0 quarters
RCKT icon
18
Rocket Pharmaceuticals
RCKT
$236M
$3.19M 1.71%
200,000
-76,802
-28% -$1.2M
2021 Q4
3 quarters
STTK icon
19
Shattuck Labs
STTK
$455M
$3.03M 1.62%
1,120,776
+100,776
+10% +$378K
2021 Q3
4 quarters
ORIC icon
20
Oric Pharmaceuticals
ORIC
$793M
$3M 1.61%
+936,334
New +$3.75M
2022 Q3
0 quarters
INCY icon
21
Incyte
INCY
$24B
$2.7M 1.44%
+40,450
New +$2.99M
2022 Q3
0 quarters
OMCL icon
22
Omnicell
OMCL
$1.59B
$2.67M 1.43%
+30,700
New +$3.23M
2022 Q3
0 quarters
AVTR icon
23
Avantor
AVTR
$10.4B
$2.4M 1.29%
+122,668
New +$3.29M
2022 Q3
0 quarters
BAX icon
24
Baxter International
BAX
$13.5B
$2.1M 1.13%
+39,000
New +$2.35M
2022 Q3
0 quarters
RYTM icon
25
Rhythm Pharmaceuticals
RYTM
$8.25B
$1.96M 1.05%
+80,000
New +$1.49M
2022 Q3
0 quarters

Similar funds

Prosight Management's Q3 2022 Portfolio in Review

As of Q3 2022, Prosight Management held 43 positions worth $187M, up 47% from $127M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management deployed $48.5M of net new capital in Q3 2022, opening 19 new positions and adding to 10 existing holdings. Its largest new stake was Horizon Therapeutics: 303,000 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was 1Life Healthcare, an estimated $9.7M trimmed.

  • Prosight Management's largest Q3 2022 buy was Horizon Therapeutics: 303,000 shares worth $18.8M.
  • Prosight Management added most to Tenet Healthcare in Q3 2022, an estimated $3.04M increase.
  • Prosight Management's biggest Q3 2022 reduction was 1Life Healthcare, cutting an estimated $9.7M.
  • Prosight Management fully exited Global Blood Therapeutics in Q3 2022, selling an estimated $3.25M.
  • Prosight Management's ten largest holdings make up 63% of its $187M portfolio in Q3 2022.
  • Prosight Management opened 19 new positions and closed 5 in Q3 2022.
  • Prosight Management's portfolio value rose 47% quarter-over-quarter to $187M.

Based on Prosight Management's 13F filing for Q3 2022, filed 14 Nov 2022.